Nanostructured Cerium-Doped ZnO Thin Film: A Breath Sensor
PublicationResearch Article

Ceramics InternationalVol. 42Pages 18289-18295

Nanostructured Cerium-Doped ZnO Thin Film: A Breath Sensor

DOI 10.1016/j.ceramint.2016.08.156

75Powered by Crossref

Highlights

  • Developed cerium-doped ZnO thin-film sensors targeting acetone and ethanolamine, biomarkers for diabetes and liver disorders.
  • Grain size decreased and optical band gap widened as cerium-dopant concentration increased.
  • 0.004 M and 0.008 M cerium-doped films gave the best response to acetone and ethanolamine respectively, with swift response and recovery.

Abstract

Cerium-doped zinc oxide (ZnO) thin films were deposited on glass by spray pyrolysis to develop a chemiresistive breath sensor for acetone and ethanolamine, biomarkers linked to diabetes mellitus and liver disorders respectively. X-ray diffraction confirmed a polycrystalline hexagonal ZnO structure across all cerium-dopant concentrations, and increasing cerium content reduced average grain size while widening the optical band gap. Films with 0.004 M and 0.008 M cerium dopant gave the best room-temperature response to acetone and ethanolamine respectively, with swift response and recovery, suggesting a non-invasive, low-cost route to disease-linked breath analysis.

Research summary

Breath analysis is an appealing, non-invasive way to screen for disease because certain volatile compounds in exhaled breath track with specific conditions — elevated acetone with diabetes mellitus, and abnormal ethanolamine with liver disorders such as primary carcinoma. This study develops cerium-doped ZnO thin-film sensors aimed at detecting these two biomarkers at room temperature.

What the study examined

  • Ce-doped ZnO thin films deposited on glass by spray pyrolysis, with cerium concentration varied
  • Crystal structure by X-ray diffraction, confirming polycrystalline hexagonal wurtzite ZnO
  • Grain size and optical band gap changes with increasing cerium-dopant concentration
  • Room-temperature sensing response, response time, and recovery time toward acetone and ethanolamine vapors

Main findings

Cerium doping produced a consistent trend: as dopant concentration increased, average grain size decreased and the optical band gap widened. Sensing tests showed that different doping levels favored different target gases — a film with 0.004 M cerium gave the best response to acetone, while a film with 0.008 M cerium gave the best response to ethanolamine, both with fast response and recovery times.

The acetone-sensitive film could detect concentrations down to about 1 ppm, in the range relevant to distinguishing diabetic from non-diabetic breath profiles.

Why it matters

By showing that cerium-doping level can be tuned to favor one breath biomarker over another, the study points toward low-cost, portable, chemiresistive sensors that field medical staff could use as a rapid first-pass indicator for conditions like diabetes mellitus or liver disorders, ahead of confirmatory clinical testing.

Citation

K. Arockia Jayalatha, E. Vignesh, Prabakaran Shankar, G. K. Mani, K. Jayanth Babu, J. B. B. Rayappan. Nanostructured Cerium-Doped ZnO Thin Film: A Breath Sensor. Ceramics International 42 (2016) 18289-18295.

DOI: 10.1016/j.ceramint.2016.08.156

Frequently Asked Questions

Why test breath for acetone and ethanolamine?

Elevated acetone in exhaled breath is linked to diabetes mellitus, and abnormal ethanolamine levels are linked to liver disorders including primary carcinoma. A sensor that flags either compound non-invasively could support early, low-cost screening.

What role does cerium doping play?

Adding cerium to the ZnO film changes its grain size and optical band gap, which in turn changes how strongly and selectively it responds to acetone versus ethanolamine at room temperature.

Is one doping level best for both gases?

No. The study found different optimal cerium concentrations for each target: 0.004 M cerium doping worked best for acetone, while 0.008 M worked best for ethanolamine.

Could this replace clinical diagnostic tests?

Not on its own. This is an author-prepared summary of a lab-scale materials study, not a validated clinical device — the authors position it as a step toward a low-cost, non-invasive screening tool, not a replacement for clinical diagnostics.